Skip to main content
EJNMMI Research

Table 2 Tumor/normal tissue (T/NT) ratios at 24 h post-injection of 111In- or 64Cu-DOTA-trastuzumab Fab

From: A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT

 

T/NT Ratio a, b, c

Tissue

111 In-DOTA-trastuzumab Fab

64 Cu-DOTA-trastuzumab Fab

Blood

9.73 ± 2.46

3.56 ± 0.62

Heart

4.31 ± 0.83

2.09 ± 0.56

Lungs

5.06 ± 1.12

1.03 ± 0.19

Liver

1.27 ± 0.26

0.59 ± 0.16

Kidneys

0.06 ± 0.02

0.09 ± 0.02

Stomach

6.99 ± 2.05

1.48 ± 0.37

Intestines

6.61 ± 1.78

1.05 ± 0.22

Spleen

1.79 ± 0.48

1.00 ± 0.20

Muscle

6.12 ± 3.33

6.78 ± 1.90

  1. 111In- or 64Cu-DOTA-trastuzumab Fab in athymic mice bearing subcutaneous MDA-MB-361 human breast cancer xenografts. aValues shown are mean ± SD (n = 4). bSignificantly different for 111In- and 64Cu-DOTA-trastuzumab Fab for lungs and intestines (both P < 0.001), blood, heart, liver, stomach (all P < 0.01) and spleen (P < 0.05). cNot significantly different for 111In- and 64Cu-DOTA-trastuzumab Fab for kidneys and muscle (P > 0.05).
Back to article page